Recent Research Analysts’ Ratings Changes for Forte Biosciences (FBRX)

Several analysts have recently updated their ratings and price targets for Forte Biosciences (NASDAQ: FBRX):

• 12/2/2025 – Forte Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Forte Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Forte Biosciences is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $65.00 price target on the stock.
• 11/25/2025 – Forte Biosciences is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $65.00 price target on the stock.
• 11/20/2025 – Forte Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Forte Biosciences had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $61.00 price target on the stock.
• 11/15/2025 – Forte Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/1/2025 – Forte Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 10/31/2025 – Forte Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/18/2025 – Forte Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 10/8/2025 – Forte Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.